Ashida Reiko, Fukutake Nobuyasu, Takada Ryoji, Ioka Tatsuya, Ohkawa Kazuyoshi, Katayama Kazuhiro, Akita Hirofumi, Takahashi Hidenori, Ohira Shingo, Teshima Teruki
Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
World J Gastrointest Oncol. 2020 Jul 15;12(7):768-781. doi: 10.4251/wjgo.v12.i7.768.
Preoperative neoadjuvant chemoradiation therapy (NACRT) is applied for resectable pancreatic cancer (RPC). To maximize the efficacy of NACRT, it is essential to ensure the accurate placement of fiducial markers for image-guided radiation. However, no standard method for delivering fiducial markers has been established to date, and the nature of RPC during NACRT remains unclear.
To determine the feasibility, safety and benefits of endoscopic ultrasound-guided (EUS) fiducial marker placement in patients with RPC.
This was a prospective case series of 29 patients (mean age, 67.5 years; 62.1% male) with RPC referred to our facility for NACRT. Under EUS guidance, a single gold marker was placed into the tumor using either a 19- or 22-gauge fine-needle aspiration needle. The differences in daily marker positioning were measured by comparing simulation computed tomography and treatment computed tomography.
In all 29 patients (100%) who underwent EUS fiducial marker placement, fiducials were placed successfully with only minor, self-limiting bleeding during puncture observed in 2 patients (6.9%). NACRT was subsequently administered to all patients and completed in 28/29 (96.6%) cases, with one patient experiencing repeat cholangitis. Spontaneous migration of gold markers was observed in 1 patient. Twenty-four patients (82.8%) had surgery with 91.7% (22/24) R0 resection, and two patients experienced complete remission. No inflammatory changes around the marker were observed in the surgical specimen. The daily position of gold markers showed large positional changes, particularly in the superior-inferior direction. Moreover, tumor location was affected by food and fluid intake as well as bowel gas, which changes daily.
EUS fiducial marker placement following NACRT for RPC is feasible and safe. The RPC is mobile and is affected by not only aspiration, but also food and fluid intake and bowel condition.
术前新辅助放化疗(NACRT)应用于可切除胰腺癌(RPC)。为使NACRT疗效最大化,确保影像引导放疗时基准标记物的准确放置至关重要。然而,迄今为止尚未建立递送基准标记物的标准方法,且NACRT期间RPC的性质仍不清楚。
确定内镜超声引导(EUS)下为RPC患者放置基准标记物的可行性、安全性和益处。
这是一项前瞻性病例系列研究,纳入29例(平均年龄67.5岁;62.1%为男性)因NACRT转诊至我院的RPC患者。在EUS引导下,使用19号或22号细针穿刺针将单个金标记物置入肿瘤内。通过比较模拟计算机断层扫描和治疗计算机断层扫描来测量每日标记物位置的差异。
在所有29例接受EUS基准标记物放置的患者(100%)中,标记物均成功放置,仅2例患者(6.9%)在穿刺时出现轻微的自限性出血。随后所有患者均接受了NACRT,28/29例(96.6%)完成治疗,1例患者发生复发性胆管炎。观察到1例患者的金标记物自发移位。24例患者(82.8%)接受了手术,R0切除率为91.7%(22/24),2例患者实现完全缓解。手术标本中未观察到标记物周围有炎症变化。金标记物的每日位置显示出较大的位置变化,尤其是在上下方向。此外,肿瘤位置受食物和液体摄入以及肠气影响,而这些因素每天都会变化。
RPC患者NACRT后行EUS基准标记物放置是可行且安全的。RPC具有移动性,不仅受抽吸影响,还受食物和液体摄入以及肠道状况影响。